Despite significant improvements in the outcome of Estrogen Receptor (ER) Î±-positive breast cancer (BC) following the use of endocrine therapies, resistance remains a major challenge.
Clinical studies proved that obesity, in addition to promote BC progression, is associated with a reduced efficacy to these treatments, but mechanisms remain unclear.
